Classement en actions
#4588
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Capitalisation boursière
$3.51B
Changement (1 jour)
-0.75%
Changement (1 an)
220.87%
Échange UniQure N.V. (QURE)
Le prix QURE avec la capitalisation boursière de B
Capitalisation boursière de UniQure N.V.(QURE)
Capitalisation boursière: $3.51B
En August 2026, UniQure N.V. a une capitalisation boursière de $3.51B. Cela fait de UniQure N.V. la 4588th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de UniQure N.V. du 2014 au 2026
QURE par rapport au top 5 des plus populaires stocks
| Prix pour QURE |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.088T
|
+144,669.88%
|
|
|
|
|
$4.629T
|
+131,615.89%
|
|
|
|
|
$4.118T
|
+117,061.78%
|
|
|
|
|
$3.687T
|
+104,801.56%
|
|
|
|
|
$2.800T
|
+79,560.94%
|
